Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | PKM | P14618 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.85 |
| ▸ | MAP3K5 | Q99683 | 10/20 | 0.79 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Claficapavir SCHEMBL13326245 | 1.00 | HIF1AN (1.00) | HIF1ANMEN1PKMKMT2AMCL1 | |
| Claficapavir SCHEMBL12697026 | 1.00 | HIF1AN (1.00) | HIF1ANMEN1PKMKMT2AMCL1 | |
| SCHEMBL21079119 | 0.94 | MEN1 (0.93) | HIF1ANMEN1PKMKMT2AMCL1 | |
| SCHEMBL26458799 | 0.92 | MEN1 (1.00) | HIF1ANMEN1PKMKMT2AMCL1 | |
| SCHEMBL6792459 | 0.91 | MAP3K5 (0.84) | HIF1ANMEN1PKMKMT2AMCL1 | |
| SCHEMBL8290210 | 0.91 | HIF1AN (0.83) | HIF1ANMEN1PKMKMT2AMCL1 | |
| SCHEMBL3905768 | 0.91 | HIF1AN (0.83) | HIF1ANMEN1PKMKMT2AMCL1 | |
| SCHEMBL3905770 | 0.91 | HIF1AN (0.83) | HIF1ANMEN1PKMKMT2AMCL1 | |
| SCHEMBL23433501 | 0.90 | HIF1AN (0.81) | HIF1ANMEN1PKMKMT2AMCL1 | |
| SCHEMBL23433454 | 0.90 | HIF1AN (0.81) | HIF1ANMEN1PKMKMT2AMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228548-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2021-07-29 | — | — | US | claimed |
| EP-3827827-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2021-06-02 | — | — | EP | claimed |
| WO-2020022789-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT | (주) 에빅스젠 | 2020-01-30 | — | — | WO | claimed |
| EP-2583969-A2 | NOVEL RHODANINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENTS | Avixgen Inc. (KR) | 2013-04-24 | — | — | EP | claimed |
| US-20130096125-A1 | NOVEL RHODANINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PAHRMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENTS | AVIXGEN INC. (KR) | 2013-04-18 | — | — | US | claimed |
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | WYETH | 2004-10-07 | — | — | US | claimed |
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2003-10-16 | — | — | US | claimed |
| EP-1128832-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2003-03-05 | — | — | EP | claimed |
| EP-1128832-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2001-09-05 | — | — | EP | claimed |
| WO-2000010573-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2000-03-02 | — | — | WO | claimed |
| US-11141407-B2 | Pharmaceutical composition for preventing or treating aids comprising rhodanine derivative | AVIXGEN INC. (KR) | 2021-10-12 | — | — | US | disclosed |
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| US-20210228548-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT | AVIXGEN INC. (KR) | 2021-07-29 | — | — | US | disclosed |
| EP-3827827-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT | Avixgen Inc. (KR) | 2021-06-02 | — | — | EP | disclosed |
| EP-3795155-A1 | PHARMACEUTICAL COMPOSITION, COMPRISING RHODANINE DERIVATIVE, FOR PREVENTION OR TREATMENT OF AIDS | Avixgen Inc. (KR) | 2021-03-24 | — | — | EP | disclosed |
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2003-10-16 | — | — | US | disclosed |
| EP-1128832-A4 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INC (US) | 2003-03-05 | — | — | EP | disclosed |
| US-20020052396-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | BAILEY THOMAS R (US) | 2002-05-02 | — | — | US | disclosed |
| EP-1128832-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | Viropharma Incorporated (US) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000010573-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING VIRAL INFECTIONS AND ASSOCIATED DISEASES | VIROPHARMA INCORPORATED (US) | 2000-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195213-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | HIF1AN 285/4885MEN1 3202/4885PKM 2154/4885 |
| US-11141407-B2 | Pharmaceutical composition for preventing or treating aids comprising rhodanine derivative | HPRT1, POLRMT, QTRT2 | HIF1AN 289/4885MEN1 4050/4885PKM 2215/4885 |
| US-20130096125-A1 | NOVEL RHODANINE DERIVATIVES, METHOD FOR PREPARING SAME, AND PAHRMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF AIDS CONTAINING THE RHODANINE DERIVATIVES AS ACTIVE INGREDIENTS | LRAT, MRM1, ADH7 | HIF1AN 267/4885MEN1 2209/4885PKM 327/4885 |
| US-20020052396-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | HIF1AN 285/4885MEN1 3202/4885PKM 2154/4885 |
| US-20040198741-A1 | Compounds, compositions and methods for treating or preventing viral infections and associated diseases | RXRG, TREH, RARG | HIF1AN 285/4885MEN1 3202/4885PKM 2154/4885 |
| US-20210228548-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING OSTEOARTHRITIS, CONTAINING RHODANINE DERIVATIVE AS ACTIVE INGREDIENT | COL2A1, COL1A1, SYVN1 | HIF1AN 354/4885MEN1 4074/4885PKM 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.